Optiver Holding
RXRX icon

Optiver Holding’s Recursion Pharmaceuticals RXRX Stock Holding History

Optiver Holding’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2,544
Closed -$7.81K – 3042
2026
Q1 		$7.81K Buy
+2,544
New +$9.83K ﹤0.01% 1282
2025
Q3 		– Sell
-2,553
Closed -$12.9K – 2853
2025
Q2 		$12.9K Buy
+2,553
New +$12.5K ﹤0.01% 936

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Optiver Holding's RXRX Position: Q2 2026 in Review

Optiver Holding sold out of Recursion Pharmaceuticals (RXRX) in Q2 2026, closing a stake of 2,544 shares — an estimated $7.81K sold.

Optiver Holding first reported a position in RXRX in Q2 2025 and held it in 2 quarters. The position peaked at $12.9K in Q2 2025. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Optiver Holding reported no remaining Recursion Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Optiver Holding sold 2,544 Recursion Pharmaceuticals shares in Q2 2026, an estimated $7.81K.
  • Optiver Holding first reported a position in Recursion Pharmaceuticals in Q2 2025 and held it in 2 quarters.
  • Optiver Holding's Recursion Pharmaceuticals position peaked at $12.9K in Q2 2025.
  • 342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Optiver Holding's 13F filing for Q2 2026, filed 12 Aug 2026.